The efficacy and safety of magnetic resonance imaging-guided high intensity focused ultrasound (MRg-HIFU) treatment of intermediate risk prostate cancer is being assessed as part of a clinical trial. Non-perfused volume (NPV) on post-treatment contrast-enhanced imaging defines the zone of ablation, however contrast administration precludes further treatment due to concern for gadolinium dissociation. Thus, pre-contrast imaging tools which can predict NPV are of value. From a cohort of 19 men who underwent MFg-HIFU for treatment of prostate cancer, we show that post-treatment DWI can predict NPV, with the potential to increase confidence in predicting the ablation zone prior to contrast administration.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords